Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show ...
EST Biogen (BIIB) up 5% after EMA recommends Leqembi for early Alzheimer’s disease Published first on TheFly – the ultimate ...
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Biotech Analyst Fadia, along with Dr. Justin Long, discuss the factors influencing adoption of Alzheimer’s disease treatments, including ...
With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...
Attend Pittcon 2025 in Boston to connect with global leaders in laboratory science and explore cutting-edge advancements in ...
The annual meeting of the American Society of Nephrology (Kidney Week) was held this year from Oct. 23 to 27 in San Diego, ...
Biogen and Idec merged in 2003 ... Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...
Q3 2024 Earnings Call Transcript October 30, 2024 Biogen Inc. misses on earnings expectations. Reported EPS is $ EPS, expectations were $3.77. Operator: Good morning. My name is Cynthia, and I will be ...
At this time, I would like to welcome everyone to the Biogen third quarter 2024 earnings call and business update. [Operator ...
Biogen’s investors are growing restless. Wednesday’s third-quarter earnings call checked most of the boxes for a successful report. The company raised its full-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback